Posted by Michael Wonder on 24 May 2021
Libtayo (cemiplimab) receives positive CHMP opinion for the treatment in Europe of two advanced cancers
24 May 2021 - CHMP has now issued three positive opinions for Libtayo in advanced cancers.
Regeneron Pharmaceuticals and Sanofi today announced that the EMA CHMP has adopted positive opinions for Libtayo (cemiplimab) as monotherapy in two advanced cancers.
